HALO - Halozyme Therapeutics, Inc.
| Previous Close | 18.91 |
| Open | 18.80 |
| Bid | 17.80 x 1800 |
| Ask | 0.00 x 1200 |
| Day's Range | 18.71 - 19.21 |
| 52 Week Range | 11.41 - 21.48 |
| Volume | 506,745 |
| Avg. Volume | 819,737 |
| Market Cap | 2.745B |
| Beta | 2.91 |
| PE Ratio (TTM) | 40.19 |
| EPS (TTM) | 0.48 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.56 |
- GlobeNewswire•7 days ago
Report: Exploring Fundamental Drivers Behind Virtu Financial, Littelfuse, Gogo, Brookfield Asset Management, Protalix BioTherapeutics, and Halozyme Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, June 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Virtu ...
- PR Newswire•9 days ago
Halozyme President And Chief Executive Officer, Dr. Helen Torley Named EY Entrepreneur Of The Year 2018 San Diego
SAN DIEGO, June 11, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced Dr. Helen Torley, president and chief executive officer, was awarded the honor of Entrepreneur Of The Year® 2018 San Diego in the category of Operational Excellence by a panel of independent judges. The EY Entrepreneur Of The Year program recognizes the endeavors of exceptional entrepreneurs who are excelling in areas such as innovation, financial performance and personal commitment to their businesses and communities. "Under Helen's leadership, Halozyme has not only made significant progress growing the ENHANZE technology franchise and studying the potential for our investigational oncology drug, but also in strengthening our culture and commitment to excellence.
Markit•12 days agoSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- PR Newswire•19 days ago
Halozyme Identifies Plasma Biomarkers As Potential Predictors Of Survival In Pancreatic Cancer
-- Janssen Presenting Five Clinical Studies of subcutaneous daratumumab with Halozyme ENHANZE Technology-- SAN DIEGO , June 1, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology ...
- PR Newswire•22 days ago
Halozyme Therapeutics To Participate In Upcoming Healthcare Conferences
SAN DIEGO , May 29, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will participate in two upcoming investor ...
- Investor's Business Daily•27 days ago
Halozyme Therapeutics Clears Technical Benchmark, Hitting 80-Plus RS Rating
On Thursday, Halozyme Therapeutics (HALO) earned a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83. [ibd-display-video id=3105496 width=50 float=left autostart=true] When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: OPKO Health and Halozyme Therapeutics
NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Major U.S. markets closed up on Monday, with the Dow Jones posting its 8th consecutive daily gain, as trade tensions between U.S. and China eased. The Dow Jones ...
- Thomson Reuters StreetEvents•last month
Edited Transcript of HALO earnings conference call or presentation 10-May-18 8:30pm GMT
Q1 2018 Halozyme Therapeutics Inc Earnings Call
- Associated Press•last month
Halozyme Therapeutics: 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 19 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- PR Newswire•last month
Halozyme Reports First Quarter 2018 Results
-- Revenue of $30.9 Million Includes a 50 Percent Increase in Royalty Revenue on a Reported Basis -- -- Eight ENHANZE®-Partnered Products Expected in Clinical Studies in 2018, Two More than Forecasted ...
Markit•last monthSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Markit•2 months agoSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- PR Newswire•2 months ago
Halozyme To Host First Quarter 2018 Financial Results Conference Call
SAN DIEGO , April 10, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference ...
- Business Wire•3 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Halozyme Therapeutics, Inc.
Levi & Korsinsky announces it has commenced an investigation of Halozyme Therapeutics, Inc. concerning possible breaches of fiduciary duty. To obtain additiona
- PR Newswire•3 months ago
Halozyme Announces Nomination Of Directors For Reelection At 2018 Stockholder Meeting
SAN DIEGO, March 22, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the nomination of Jean-Pierre Bizzari, M.D. and James M. Daly as Class II directors for reelection at the Company's 2018 stockholder meeting. Following communication by Randal J. Kirk of his unavailability for further service due to growing commitments outside Halozyme, it has been agreed that Mr. Kirk will not be nominated for reelection to the board of directors. Mr. Kirk joined the board of directors nearly 11 years ago at a formative time for the company and remains Halozyme's largest shareholder.
- PR Newswire•3 months ago
Halozyme To Present Data From Six Nonclinical Studies At American Association Of Cancer Research Annual Conference
SAN DIEGO , March 14, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will present nonclinical data from ...
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of HALO earnings conference call or presentation 20-Feb-18 9:30pm GMT
Q4 2017 Halozyme Therapeutics Inc Earnings Call
- PR Newswire•4 months ago
Halozyme Therapeutics To Present At Upcoming Healthcare Conference
SAN DIEGO , Feb. 27, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will be presenting at the Cowen & Company ...
Markit•4 months agoSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc NASDAQ/NGS:HALO
- ACCESSWIRE•4 months ago
Today’s Research Reports on Stocks to Watch: Halozyme Therapeutics and Loxo Oncology
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Halozyme shares closed up roughly 4% on Wednesday after the company announced strong fourth quarter results earlier in the week. Shares of Loxo Oncology ...
- Associated Press•4 months ago
Halozyme Therapeutics tops Street 4Q forecasts
The San Diego-based company said it had profit of 85 cents per share. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings ...
- PR Newswire•4 months ago
Halozyme Reports Fourth Quarter And Full-Year 2017 Results
-- Continued Momentum from ENHANZE® Technology with Q4 Royalty Revenue Increasing 24 Percent from Prior-Year Period to $17.7 million -- -- HALO-301 Study of Investigational New Drug PEGPH20 Remains on ...
- ACCESSWIRE•4 months ago
Halozyme Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 20, 2018 / Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 20, 2018 at 4:30 PM ...
Markit•4 months agoSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc NASDAQ/NGS:HALO
